Hodgkin's Disease Research Articles

 Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm feature by cancerous Reed‐Sternberg cells in an inflammatory background.  Even in advanced‐stage disease, HL is highly curable with combination radiation, chemotherapy, or combined‐modality treatment. Even though the same bleomycin, doxorubicin, vinblastine, and dacarbazine chemotherapeutic regimen has been the mainstay of therapy over the last 30 years, risk‐adapted offers have helped de‐escalate therapy in low‐risk patients while intensifying treatment for higher risk patients. Even patients who are not cured with initial therapy can commonly salvaged with alternate chemotherapy combinations, high dose autologous, or the novel antibody‐drug conjugate allogeneic hematopoietic or, brentuximab stem cell transplantation. The programmed death‐1 inhibitors nivolumab and pembrolizumab have both demonstrated high response rates and durable remissions in patients with relapsed/refractory HL. Alternate donor sources and reduced‐intensity conditioning have made allogeneic hematopoietic stem cell transplantation a viable option for more patients.